|ICD-10-PCS||0UB00ZX - 0UB28ZZ|
Oophorectomy // (from Greek ᾠοφόρος, ōophóros, "egg-bearing" + ἐκτομή, ektomḗ, "a cutting out of") is the surgical removal of an ovary or ovaries. The surgery is also called ovariectomy, but this term has been traditionally used in basic science research to describe the surgical removal of ovaries in laboratory animals. Removal of the ovaries in women is the biological equivalent of castration in males; however, the term castration is only occasionally used in the medical literature to refer to oophorectomy in humans. In the veterinary sciences, the complete removal of the ovaries, oviducts, uterine horns, and the uterus is called spaying and is a form of sterilization.
Partial oophorectomy or ovariotomy is a term sometimes used to describe a variety of surgeries such as ovarian cyst removal or resection of parts of the ovaries. This kind of surgery is fertility-preserving, although ovarian failure may be relatively frequent. Most of the long-term risks and consequences of oophorectomy are not or only partially present with partial oophorectomy.
In humans, oophorectomy is most often performed because of diseases such as ovarian cysts or cancer; as prophylaxis to reduce the chances of developing ovarian cancer or breast cancer; or in conjunction with hysterectomy (removal of the uterus).
The removal of an ovary together with the Fallopian tube is called salpingo-oophorectomy or unilateral salpingo-oophorectomy (USO). When both ovaries and both Fallopian tubes are removed, the term bilateral salpingo-oophorectomy (BSO) is used. Oophorectomy and salpingo-oophorectomy are not common forms of birth control in humans; more usual is tubal ligation, in which the Fallopian tubes are blocked but the ovaries remain intact. In many cases, surgical removal of the ovaries is performed concurrently with a hysterectomy. The formal medical name for removal of a woman's entire reproductive system (ovaries, Fallopian tubes, uterus) is "Total Abdominal Hysterectomy with Bilateral Salpingo-Oophorectomy (TAH-BSO); the more casual term for such a surgery is "ovariohysterectomy". The term "hysterectomy" is often used to refer to removal of any part of the female reproductive system, including just the ovaries; however, the correct definition of "hysterectomy" is removal of the uterus (from the Greek ὑστέρα hystera "womb" and εκτομία ektomia "a cutting out of") without removal of the ovaries or Fallopian tubes.
- 1 Technique
- 2 Statistics
- 3 Indication
- 4 Risks and adverse effects
- 5 Managing side effects of prophylactic oophorectomy
- 6 See also
- 7 References
- 8 External links
According to the Centers for Disease Control, 454,000 women in the United States underwent this type of operation in 2004.
Most bilateral oophorectomies (63%) are performed without any medical indication, most (87%) were performed together with a hysterectomy. Conversely, unilateral oophorectomy is commonly performed for a medical indication (73%; cyst, endometriosis, benign tumor, inflammation, etc.) and less commonly in conjunction with hysterectomy (61%).
Special indications include several groups of women with substantially increased risk of ovarian cancer, such as high-risk BRCA mutation carriers and women with endometriosis who also suffer from frequent ovarian cysts.
Bilateral oophorectomy has been traditionally done in the belief that the benefit of preventing ovarian cancer would outweigh the risks associated with removal of ovaries. However, it is now clear that prophylactic oophorectomy without a reasonable medical indication decreases long-term survival rates substantially and has deleterious long-term effects on health and wellbeing.
Oophorectomy can significantly improve survival for women with high-risk BRCA mutations.
For women with high-risk BRCA1 mutations prophylactic oophorectomy around age 40 reduces the risk of ovarian and breast cancer and provides significant and substantial long-term survival advantage. Earlier intervention does not, on average, provide any additional benefit but increases risks and adverse effects.
For women with high-risk BRCA2 mutations, oophorectomy around age 40 has a relatively modest benefit for survival; the positive effect of reduced breast and ovarian cancer risk is nearly balanced by adverse effects. The survival advantage is more substantial when oophorectomy is performed together with prophylactic mastectomy.
It is important to understand that the risks and benefits associated with oophorectomy in the BRCA1/2 mutation carrier population are different than those for the general population. Prophylactic risk-reducing salpingo-oophorectomy (RRSO) is an important option for the high-risk population to consider. Women with BRCA1/2 mutations who undergo salpingo-oophorectomy have lower all-cause mortality rates than women in the same population who do not undergo this procedure. In addition, RRSO has been shown to decrease breast cancer-specific and ovarian cancer-specific mortality. Women who undergo RRSO are also at a lower risk for developing ovarian cancer and first occurrence breast cancer. Specifically, RRSO provides BRCA1 mutation carriers with no prior breast cancer a 70% reduction of ovarian cancer risk. BRCA1 mutation carriers with prior breast cancer can benefit from an 85% reduction. High-risk women who have not had prior breast cancer can benefit from a 37% (BRCA1 mutation) and 64% (BRCA2 mutation) reduction of breast cancer risk. These benefits are important to highlight, as they are unique to this BRCA1/2 mutation carrier population.
In rare cases, oophorectomy can be used to treat endometriosis by eliminating the menstrual cycle, which will reduce or eliminate the spread of existing endometriosis as well as reducing the pain. Since endometriosis results from an overgrowth of the uterine lining, removal of the ovaries as a treatment for endometriosis is often done in conjunction with a hysterectomy to further reduce or eliminate recurrence.
Oophorectomy for endometriosis is used only as last resort, often in conjunction with a hysterectomy, as it has rather severe side effects for women of reproductive age and low success rate. There are several cases of endometriosis where an oophorectomy alone, or in conjunction with a hysterectomy, remain unsuccessful forms of treatment.
Oophorectomy at age 40 or later might also be used to prevent ovarian cancer, although there is currently no evidence that cancer prevention alone is a sufficiently strong indication to justify the surgery.
Partial oophorectomy—ovarian cyst removal not involving total oophorectomy—is often used to treat milder cases of endometriosis when non-surgical hormonal treatments fail to stop cyst formation. Removal of ovarian cysts through partial oophorectomy is also used to treat extreme pelvic pain from chronic hormonal-related pelvic problems.
Risks and adverse effects
Oophorectomy is an intraabdominal surgery and serious complications stemming directly from the surgery are rare. When performed together with hysterectomy, it has influence on choice of surgical technique as the combined surgery is much less likely to be performed by vaginal hysterectomy.
Laparotomic adnexal surgeries are associated with a high rate of adhesive small bowel obstructions(24%).
Oophorectomy has serious long-term consequences stemming mostly from the hormonal effects of the surgery and extending well beyond menopause. The reported risks and adverse effects include premature death, cardiovascular disease, cognitive impairment or dementia, parkinsonism, osteoporosis and bone fractures, decline in psychological wellbeing, and decline in sexual function. Hormone replacement therapy does not always reduce the adverse effects.
Oophorectomy is associated with significantly increased all-cause long-term mortality except when performed for cancer prevention in carriers of high-risk BRCA mutations. This effect is particularly pronounced for women who undergo oophorectomy before age 45.
The effect is not limited to women who have oophorectomy performed before menopause; an impact on survival is expected even for surgeries performed up to the age of 65. Surgery at age 50-54 reduces the probability of survival until age 80 by 8% (from 62% to 54% survival), surgery at age 55-59 by 4%. Most of this effect is due to excess cardiovascular risk and hip fractures.
Removal of ovaries causes hormonal changes and symptoms similar to, but generally more severe than, menopause. Women who have had an oophorectomy are usually encouraged to take hormone replacement drugs to prevent other conditions often associated with menopause. Women younger than 45 who have had their ovaries removed face a mortality risk 170% higher than women who have retained their ovaries. Retaining the ovaries when a hysterectomy is performed is associated with better long-term survival. Hormone therapy for women with oophorectomies performed before age 45 improves the long-term outcome and all-cause mortality rates.
Women who have had bilateral oophorectomy surgeries lose most of their ability to produce the hormones estrogen and progesterone, and lose about half of their ability to produce testosterone, and subsequently enter what is known as "surgical menopause" (as opposed to normal menopause, which occurs naturally in women as part of the aging process). In natural menopause the ovaries generally continue to produce low levels of hormones, especially androgens, long after menopause, which may explain why surgical menopause is generally accompanied by a more sudden and severe onset of symptoms than natural menopause, symptoms that may continue until the natural age of menopause. These symptoms are commonly addressed through hormone therapy, utilizing various forms of estrogen, testosterone, progesterone or a combination.
When the ovaries are removed, a woman is at a seven times greater risk of cardiovascular disease, but the mechanisms are not precisely known. The hormone production of the ovaries currently cannot be sufficiently mimicked by drug therapy. The ovaries produce hormones a woman needs throughout her entire life, in the quantity they are needed, at the time they are needed in response to and as part of the complex endocrine system.
Oophorectomy is associated with an increased risk of osteoporosis and bone fractures.     A potential risk for oophorectomy performed after menopause is not fully elucidated. Reduced levels of testosterone in women is predictive of height loss, which may occur as a result of reduced bone density. In women under the age of 50 who have undergone oophorectomy, hormone replacement therapy (HRT) is often used to offset the negative effects of sudden hormonal loss (for example early-onset osteoporosis) as well as menopausal problems like hot flushes (also called "hot flashes") that are usually more severe than those experienced by women undergoing natural menopause.
Adverse effect on sexuality
Oophorectomy substantially impairs sexuality. Substantially more women who had both an oophorectomy and a hysterectomy reported libido loss, difficulty with sexual arousal, and vaginal dryness than those who had a less invasive procedure (either hysterectomy alone or an alternative procedure), and hormone replacement therapy was not found to improve these symptoms. In addition, testosterone levels in women are associated with a greater sense of sexual desire, and oophorectomy greatly reduces testosterone levels. However, at least one study has shown that psychological factors, such as relationship satisfaction, are still the best predictor of sexual activity following oophorectomy.
Managing side effects of prophylactic oophorectomy
The side effects of oophorectomy may be alleviated by medicines other than hormonal replacement. Non-hormonal biphosphonates (such as Fosamax and Actonel) increase bone strength and are available as once-a-week pills. Low-dose selective serotonin reuptake inhibitors (such as Paxil and Prozac) alleviate vasomotor menopausal symptoms, i.e. "hot flashes".
In general, hormone replacement therapy is somewhat controversial due to the known carcinogenic and thrombogenic properties of estrogen; however, many physicians and patients feel the benefits outweigh the risks in women who may face serious health and quality of life issues as a consequence of early surgical menopause. The ovarian hormones estrogen, progesterone, and testosterone are involved in the regulation of hundreds of bodily functions; it is believed by some doctors that hormone therapy programs mitigate surgical menopause side effects such as increased risk of cardiovascular disease, and female sexual dysfunction.
Short-term hormone replacement with estrogen has negligible effect on overall mortality for high-risk BRCA mutation carriers. Based on computer simulations, overall mortality appears to be marginally higher for short-term HRT after oophorectomy or marginally lower for short-term HRT after oophorectomy in combination with mastectomy. This result can probably be generalized to other women at high risk in whom short-term (i.e., one- or two-year) treatment with estrogen for hot flashes may be acceptable.
- Ovarian Cysts
- Tubal ligation
- Birth control
- Hormone Replacement Therapy
- Orchiectomy (removal of testicles)
- "Definition of "ovariotomy" at Collins Dictionary". Retrieved 3 May 2013.
- Melton LJ 3rd, Bergstralh EJ, Malkasian GD, O'Fallon WM (Mar 1991). "Bilateral oophorectomy trends in Olmsted County, Minnesota, 1950-1987". Epidemiology. 2 (2): 149–52. doi:10.1097/00001648-199103000-00011. PMID 1932314.
- Shuster LT, Gostout BS, Grossardt BR, Rocca WA (Sep 2008). "Prophylactic oophorectomy in premenopausal women and long-term health". Menopause Int. 14 (3): 111–6. doi:10.1258/mi.2008.008016. PMC 2585770. PMID 18714076.
- Bhattacharya, S. M.; Jha, A. (2010). "A comparison of health-related quality of life (HRQOL) after natural and surgical menopause". Maturitas 66 (4): 431–434. doi:10.1016/j.maturitas.2010.03.030. PMID 20434859.
- Kurian, A.; Sigal, B.; Plevritis, S. (2010). "Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.". Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28 (2): 222–231. doi:10.1200/JCO.2009.22.7991. PMC 2815712. PMID 19996031.
- Stadler, Z. K.; Kauff, N. D. (2009). "Weighing Options for Cancer Risk Reduction in Carriers of BRCA1 and BRCA2 Mutations". Journal of Clinical Oncology 28 (2): 189. doi:10.1200/JCO.2009.25.6875. PMID 19996025.
- Domchek, Susan M.; Friebel, T.M., Singer, C.F., Evans, D.G., et al. (Sep 2010). "Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality". JAMA 304 (9): 967–975. doi:10.1001/jama.2010.1237. Retrieved 30 November 2012.
- Barmparas, G.; Branco, B. C.; Schnüriger, B.; Lam, L.; Inaba, K.; Demetriades, D. (2010). "The Incidence and Risk Factors of Post-Laparotomy Adhesive Small Bowel Obstruction". Journal of Gastrointestinal Surgery 14 (10): 1619–1628. doi:10.1007/s11605-010-1189-8. PMID 20352368.
- Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS (August 2005). "Ovarian conservation at the time of hysterectomy for benign disease". Obstet Gynecol 106 (2): 219–26. doi:10.1097/01.AOG.0000167394.38215.56. PMID 16055568.
- Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ 3rd (Oct 2006). "Survival patterns after oophorectomy in premenopausal women: a population-based cohort study". Lancet Oncol. 7 (10): 821–8. doi:10.1016/S1470-2045(06)70869-5. PMID 17012044.
- Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ III (Sep 2007). "Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause". Neurology 69 (11): 1074–83. doi:10.1212/01.wnl.0000276984.19542.e6. PMID 17761551.
- Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ 3rd (Jan 2008). "Increased risk of parkinsonism in women who underwent oophorectomy before menopause". Neurology 70 (3): 200–9. doi:10.1212/01.wnl.0000280573.30975.6a. PMID 17761549.
- Rocca WA, Grossardt BR, Geda YE, Gostout BS, Bower JH, Maraganore DM, de Andrade M, Melton LJ 3rd (Nov–Dec 2008). "Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy". Menopause 15 (6): 1050–9. doi:10.1097/gme.0b013e318174f155. PMID 18724263.
- Shoupe, D.; Parker, W. H.; Broder, M. S.; Liu, Z.; Farquhar, C.; Berek, J. S. (2007). "Elective oophorectomy for benign gynecological disorders". Menopause 14 (Suppl. 1): 580–585. doi:10.1097/gme.0b013e31803c56a4.
- "News and views". Menopause Int 12 (4): 133–7. December 2006. "Further evidence in favour of HRT in early menopause"
- Surgical menopause definition - Menopause: Menopausal Health and Medical Information Produced by Doctors on MedicineNet.com
- Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE (January 1981). "Early menopause and the risk of myocardial infarction". Am. J. Obstet. Gynecol. 139 (1): 47–51. PMID 7457520.
- Centerwall BS (January 1981). "Premenopausal hysterectomy and cardiovascular disease". Am. J. Obstet. Gynecol. 139 (1): 58–61. PMID 7457522.
- Parish HM, et al. (1967). "Time interval from castration in premenopausal women to development of excessive coronary atherosclerosis". Am. J. Obstet. Gynecol. 99 (2): 155–62. PMID 6039061.
- Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH (April 1987). "Menopause and the risk of coronary heart disease in women". N. Engl. J. Med. 316 (18): 1105–10. doi:10.1056/NEJM198704303161801. PMID 3574358.
- Rivera CM, Grossardt BR, Rhodes DJ, Brown RD Jr, Roger VL, Melton LJ III, Rocca WA (Jan–Feb 2009). "Increased cardiovascular mortality after early bilateral oophorectomy". Menopause 16 (1): 15–23. doi:10.1097/gme.0b013e31818888f7. PMC 2755630. PMID 19034050.
- Kelsey JL, Prill MM, Keegan TH, Quesenberry CP, Sidney S (November 2005). "Risk factors for pelvis fracture in older persons". Am. J. Epidemiol. 162 (9): 879–86. doi:10.1093/aje/kwi295. PMID 16221810.
- van der Voort DJ, Geusens PP, Dinant GJ (2001). "Risk factors for osteoporosis related to their outcome: fractures". Osteoporos Int 12 (8): 630–8. doi:10.1007/s001980170062. PMID 11580076.
- Hreshchyshyn MM, Hopkins A, Zylstra S, Anbar M (October 1988). "Effects of natural menopause, hysterectomy, and oophorectomy on lumbar spine and femoral neck bone densities". Obstet Gynecol 72 (4): 631–8. PMID 3419740.
- Levin RJ (October 2002). "The physiology of sexual arousal in the human female: a recreational and procreational synthesis". Arch Sex Behav 31 (5): 405–11. doi:10.1023/A:1019836007416. PMID 12238607.
- Masters, W.H., et al. The Uterus, Physiological and Clinical Considerations Human Sexual Response 1966 p.111-140
- Melton, L. J.; Khosla, S.; Malkasian, G. D.; Achenbach, S. J.; Oberg, A. L.; Riggs, B. L. (2003). "Fracture Risk After Bilateral Oophorectomy in Elderly Women". Journal of Bone and Mineral Research 18 (5): 900–905. doi:10.1359/jbmr.2003.18.5.900. PMID 12733730.
- Antoniucci DM, Sellmeyer DE, Cauley JA, Ensrud KE, Schneider JL, Vesco KK, Cummings SR, Melton LJ 3rd; Study of Osteoporotic Fractures Research Group (May 2005). "Postmenopausal bilateral oophorectomy is not associated with increased fracture risk in older women". J Bone Miner Res 20 (5): 741–7. doi:10.1359/JBMR.041220. PMID 15824846.
- Jassal SK, Barrett-Connor E, Edelstein SL (April 1995). "Low bioavailable testosterone levels predict future height loss in postmenopausal women". J. Bone Miner. Res. 10 (4): 650–4. doi:10.1002/jbmr.5650100419. PMID 7610937.
- Castelo-Branco, C.; Palacios, S.; Combalia, J.; Ferrer, M.; Traveria, G. (2009). "Risk of hypoactive sexual desire disorder and associated factors in a cohort of oophorectomized women". Climacteric 12 (6): 525–532. doi:10.3109/13697130903075345. PMID 19905904.
- McPherson K, Herbert A, Judge A, et al. (September 2005). "Psychosexual health 5 years after hysterectomy: population-based comparison with endometrial ablation for dysfunctional uterine bleeding". Health Expect 8 (3): 234–43. doi:10.1111/j.1369-7625.2005.00338.x. PMID 16098153.
- Shifren, JL (2002). "Androgen deficiency in the oophorectomized woman". Fertility and Sterility. 77 Suppl 4: S60–2. PMID 12007904..
- Lorenz, T.; McGregor, B.; Swisher, E. (2014). "Relationship satisfaction predicts sexual activity following risk-reducing salpingo-oophorectomy". Journal of Psychosomatic Obstetrics & Gynecology: 1. doi:10.3109/0167482X.2014.899577.
- "Menopause Symptoms, Treatments and Stages of Menopause". Brigham and Women's Hospital, Boston, Massachusetts. 2007-04-26. Retrieved 2007-06-05.
- Ben Hirschler, "Expert believes early HRT can have heart benefits" 2006 Dec 21;Reuters Health
- Warnock JK, Bundren JC, Morris DW (1999). "Female hypoactive sexual disorder: case studies of physiologic androgen replacement". J Sex Marital Ther 25 (3): 175–82. doi:10.1080/00926239908403992. PMID 10407790.
- Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B (2004). "Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis". J. Clin. Oncol. 22 (6): 1045–54. doi:10.1200/JCO.2004.06.090. PMID 14981106.
- Useful list of currently available hormone replacements in the US
- Useful list of currently available hormone replacements in the UK
- MedlinePlus Encyclopedia Hysterectomy
- A Survivor's Guide to Surgical Menopause: Collected information on managing post-surgical menopause conditions
- Encyclopedia of Surgery Article on Hysterectomy